PHAT

Phathom Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

12.180

-0.18(-1.456%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

12.460

Open

12.460

VWAP

12.07

Vol

601.07K

Mkt Cap

864.09M

Low

11.780

Amount

7.25M

EV/EBITDA(TTM)

Total Shares

58.54M

1.29B

EV/OCF(TTM)

P/S(TTM)

7.48

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

57.30M

+100.92%

-0.470

-64.12%

54.92M

+85.15%

-0.377

-64.13%

47.03M

+187.63%

-0.555

-57.95%

Estimates Revision

The market is revising Upward the revenue expectations for Phathom Pharmaceuticals, Inc. (PHAT) for FY2025, with the revenue forecasts being adjusted by 6.54% over the past three months. During the same period, the stock price has changed by 162.50%.

Revenue Estimates for FY2025

Revise Upward

+6.54%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-1.35%

In Past 3 Month

Stock Price

Go Up

+162.50%

In Past 3 Month

7 Analyst Rating

77.09% Upside

Wall Street analysts forecast PHAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHAT is 21.57 USD with a low forecast of 12.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

77.09% Upside

Current: 12.180

Low

12.00

Averages

21.57

High

29.00

77.09% Upside

Current: 12.180

Low

12.00

Averages

21.57

High

29.00

Cantor Fitzgerald

NULL

Overweight

upgrade

$23 -> $29

2025-06-06

Reason

Cantor Fitzgerald

Price Target

$23 -> $29

2025-06-06

upgrade

NULL

Overweight

Reason

Cantor Fitzgerald raised the firm's price target on Phathom Pharmaceuticals to $29 from $23 and keeps an Overweight rating on the shares. The FDA has granted Phathom Pharmaceuticals 10-year exclusivity for Voquenza, which extends the exclusivity period to May 2032 instead of 2030, adding about $6 per share to the firm's distributable cash flow estimates, the analyst tells investors in a research note. Cantor says the overhang has been removed and continues to view Voquenza as a "great" drug in the acid-suppression space with more room to grow.

Needham

Joseph Stringer

Strong Buy

Reiterates

$28

2025-04-21

Reason

Needham

Joseph Stringer

Price Target

$28

2025-04-21

Reiterates

Strong Buy

Reason

Goldman Sachs

Paul Choi

Hold

Maintains

$12 → $10

2025-04-17

Reason

Goldman Sachs

Paul Choi

Price Target

$12 → $10

2025-04-17

Maintains

Hold

Reason

Needham

Joseph Stringer

Strong Buy

Reiterates

$28

2025-04-09

Reason

Needham

Joseph Stringer

Price Target

$28

2025-04-09

Reiterates

Strong Buy

Reason

Guggenheim

Yatin Suneja

Strong Buy

Reiterates

n/a

2025-04-02

Reason

Guggenheim

Yatin Suneja

Price Target

n/a

2025-04-02

Reiterates

Strong Buy

Reason

Needham

Joseph Stringer

Strong Buy

Reiterates

$28

2025-04-02

Reason

Needham

Joseph Stringer

Price Target

$28

2025-04-02

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Phathom Pharmaceuticals Inc (PHAT.O) is -7.05, compared to its 5-year average forward P/E of -4.13. For a more detailed relative valuation and DCF analysis to assess Phathom Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.13

Current PE

-7.05

Overvalued PE

-0.90

Undervalued PE

-7.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.35

Current EV/EBITDA

-25.14

Overvalued EV/EBITDA

-0.86

Undervalued EV/EBITDA

-7.84

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

119.16

Current PS

3.69

Overvalued PS

342.05

Undervalued PS

-103.74

Financials

Annual

Quarterly

FY2025Q2

YoY :

+439.36%

39.50M

Total Revenue

FY2025Q2

YoY :

-32.83%

-51.92M

Operating Profit

FY2025Q2

YoY :

-17.10%

-75.81M

Net Income after Tax

FY2025Q2

YoY :

-32.69%

-1.05

EPS - Diluted

FY2025Q2

YoY :

-11.22%

-62.83M

Free Cash Flow

FY2025Q2

YoY :

+7.44%

87.25

Gross Profit Margin - %

FY2025Q2

-241.02

FCF Margin - %

FY2025Q2

YoY :

-84.63%

-191.91

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

14.2K

USD

3-6

Months

16.7K

USD

6-9

Months

221.2K

USD

0-12

Months

19.3K

USD

Bought

0-3

0.0

USD

Months

3-6

139.6K

USD

Months

6-9

44.2K

USD

Months

0-12

180.3K

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

828.8K

Volume

0-12

Months

0.0

Volume

Bought

0-3

1.9M

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

1.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

14.2K

USD

3-6

Months

16.7K

USD

6-9

Months

221.2K

USD

0-12

Months

19.3K

USD

Bought

0-3

0.0

USD

Months

3-6

139.6K

USD

Months

6-9

44.2K

USD

Months

0-12

180.3K

USD

Months

PHAT News & Events

Events Timeline

2025-08-07 (ET)

2025-08-07

07:27:11

Phathom Pharmaceuticals reports Q2 EPS (79c), consensus (89c)

2025-07-17 (ET)

2025-07-17

11:58:09

Avidity, Phathom mentioned as potential takeout targets at Needham

2025-06-23 (ET)

2025-06-23

08:02:32

Phathom Pharmaceuticals appoints Anne Marie Cook as CLO, corporate secretary

News

5.0

08-20Newsfilter

Phathom Pharmaceuticals Confirms No Decrease in Lead Shareholder's Ownership After 13D Filing Administrative Update

5.0

06-23Newsfilter

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

9.0

06-16NASDAQ.COM

Phathom Pharma: FDA Updates Orange Book To Reflect 10 Year NCE Regulatory Exclusivity For VOQUEZNA

People Also Watch

Global Indemnity Group LLC

Village Super Market Inc

Bar Harbor Bankshares

Titan International Inc

Entrada Therapeutics Inc

Ballard Power Systems Inc

2.020

USD

-0.49%

Kimball Electronics Inc

28.870

USD

+0.03%

FAQ

What is Phathom Pharmaceuticals Inc (PHAT) stock price today?

The current price of PHAT is 12.18 USD — it has decreased -1.46 % in the last trading day.

PHAT

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

PHAT News & Events

Events Timeline

News

People Also Watch

FAQ

What is Phathom Pharmaceuticals Inc (PHAT) stock price today?

What is Phathom Pharmaceuticals Inc (PHAT)'s business?

What is the price predicton of PHAT Stock?

What is Phathom Pharmaceuticals Inc (PHAT)'s revenue for the last quarter?

What is Phathom Pharmaceuticals Inc (PHAT)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Phathom Pharmaceuticals Inc (PHAT)'s fundamentals?

How many employees does Phathom Pharmaceuticals Inc (PHAT). have?

What is Phathom Pharmaceuticals Inc (PHAT) market cap?